Scarica l'app Stockscreener
11.96
2.29%
-0.28
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Precedente Chiudi:
$12.24
Aprire:
$12.02
Volume 24 ore:
1.13M
Relative Volume:
0.49
Capitalizzazione di mercato:
$1.36B
Reddito:
-
Utile/perdita netta:
$-294.51M
Rapporto P/E:
-3.3596
EPS:
-3.56
Flusso di cassa netto:
$-244.42M
1 W Prestazione:
+2.31%
1M Prestazione:
+2.05%
6M Prestazione:
-60.93%
1 anno Prestazione:
-61.67%
Intervallo 1D:
$11.51
$12.10
Intervallo di 1 settimana:
$11.51
$12.34
Portata 52W:
$6.36
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Nome
Dyne Therapeutics Inc
Settore
Industria
Telefono
(781) 786-8230
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Confronta DYN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
11.96 | 1.33B | 0 | -294.51M | -244.42M | -3.56 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Reiterato | Chardan Capital Markets | Buy |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-27 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Iniziato | Oppenheimer | Outperform |
| 2023-01-26 | Iniziato | Guggenheim | Buy |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Outperform |
| 2020-10-12 | Iniziato | JP Morgan | Overweight |
| 2020-10-12 | Iniziato | Jefferies | Buy |
| 2020-10-12 | Iniziato | Piper Sandler | Overweight |
| 2020-10-12 | Iniziato | Stifel | Buy |
Mostra tutto
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Evercore ISI - Defense World
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages - Defense World
Dyne Therapeutics (DYN) Receives Outperform Rating as Confidence Grows | DYN Stock News - GuruFocus
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
Ameriprise Financial Inc. Increases Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Deutsche Bank AG Has $1.67 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics Inc (DYN) Volatility Hits 6.09%: What Good Investors Need To Be Aware Of - Stocksregister
How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com
66,998 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by BNP Paribas Financial Markets - Defense World
Antibody Conjugate Oligonucleotide Market Research 2025-2035, Competitive Analysis of Key PlayersAvidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, and AstraZenecaResearchAndMarkets.com - Bluefield Daily Telegraph
Dimensional Fund Advisors LP Sells 66,569 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Northern Trust Corp Increases Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
H.C. Wainwright cuts Dyne Therapeutics target to $38 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Dyne Therapeutics target to $38 - Investing.com
H.C. Wainwright Adjusts Price Target for Dyne Therapeutics (DYN) - GuruFocus
Dyne Therapeutics (DYN) Price Target Lowered by HC Wainwright & Co. | DYN Stock News - GuruFocus
Chardan Capital Reconfirms Buy Rating for Dyne Therapeutics (DYN - GuruFocus
RBC Cuts Price Target on Dyne Therapeutics to $30 From $36, Keeps Outperform, Speculative Risk - marketscreener.com
H.C. Wainwright Adjusts Price Target for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus
Chardan Capital Reconfirms Buy Rating for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus
Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Dyne Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates - Nasdaq
Dyne (DYN) Eyes Accelerated Approval for Key Programs by 2026 | DYN Stock News - GuruFocus
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | DYN Stock News - GuruFocus
Dyne Therapeutics, Inc. SEC 10-Q Report - TradingView
Dyne Therapeutics, Inc. (NASDAQ:DYN) Stake Cut by Invesco Ltd. - Defense World
Wells Fargo & Company MN Raises Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Raymond James Financial Inc. Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Investors Who Lost Money on Dyne Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationDYN - ACCESS Newswire
Is Dyne Therapeutics Inc. (NASDAQ:DYN) the Most Promising Small-Cap Stock According to Analysts? - Insider Monkey
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy - Yahoo Finance
11 Most Promising Small-Cap Stocks According to Analysts - Insider Monkey
Dyne Therapeutics Gets EU Orphan Drug Status for Duchenne Treatment - marketscreener.com
Dyne Therapeutics stock rises on orphan drug status By Investing.com - Investing.com Canada
Dyne Therapeutics stock rises on orphan drug status - Investing.com
Dyne Therapeutics (DYN) Gains EU Orphan Drug Status for DYNE-251 - GuruFocus
Dyne Therapeutics Receives European Medicines Agency (EMA) Orpha - GuruFocus
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation For DYNE-251 In Duchenne Muscular Dystrophy - marketscreener.com
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy - The Manila Times
Dyne Therapeutics Receives European Medicines Agency (EMA) - GlobeNewswire
Breakthrough DMD Treatment DYNE-251 Wins Crucial EU Orphan Status as Phase 1/2 Trial Shows Promise - Stock Titan
JPMorgan Chase & Co. Has $2.32 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.06m - simplywall.st
Biotech stocks jump as Makary outlines FDA vision, RBC comments By Investing.com - Investing.com India
Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha
Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne - Endpoints News
More C-suite changes at Dyne - BioCentury
Dyne Therapeutics reshapes leadership team ahead of drug launches By Investing.com - Investing.com South Africa
Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):